Aydin Unal *,Ismail Kocyigit ,Feridun Kavuncuoglu ,Murat Hayri Sipahioglu ,Bulent Tokgoz ,Oktay Oymak ,Cengiz Utas
Aim: Hypomagnesemia is a frequent complication in RTRs, particularly in the early post-transplant period. Hypomagnesemia is usually associated with the use of calcineurin inhibitors. The relationship between cyclosporine use and hypomagnesemia is well known. However, it has been reported in several studies that hypomagnesemia was seen more in RTRs treated with tacrolimus compared to those treated with cyclosporine. In this study, we aimed to investigate the frequency and risk factors of post-transplant hypomagnesemia and effects of calcineurin inhibitors on hypomagnesemia among Turkish patients.
Patients and method: The study included 68 adult renal transplantation recipients. Hypomagnesemia was defined as serum magnesium level <1.4 mEq/L.
Result: Hypomagnesemia were found in 26 (38.2%) of the 68 patients. Levels of serum calcium and glucose were significantly higher in hypomagnesemic group compared to normomagnesemic group (9.7 ± 0.5 mg/dL vs. 8.4 ± 0.5, p: 0.029 and 107.3 ± 19.1 mg/dL vs. 95.8 ± 16.1, p: 0.010, respectively). Post-transplant duration was meaningfully longer in normomagnesemic group (9.5 months vs. 46.5, p: 0.001). Serum magnesium level was meaningfully higher in patients with cyclosporine compared to patients treated with tacrolimus (1.44 ± 0.5 mEq/L vs. 1.52 ± 0.2, p: 0.002, respectively). Post-transplant duration was significantly longer in cyclosporine group (12 months vs. 98.5, p: 0.001). Frequency of hypomagnesemia was significantly higher tacrolimus group (58% vs. 10%, p: 0.001).
Conclusion: The frequency of hypomagnesemia was high among Turkish renal transplant recipients, especially those treated with tacrolimus. Increased concentrations of serum calcium and glucose and the shorter post-transplant duration were risk factors for post-transplant hypomagnesemia.
இந்தக் கட்டுரையைப் பகிரவும்
English 
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi 